New guidelines released jointly by the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) stress the importance of lowering lipid levels on a population level, particularly in high-risk individuals, based on CVD risk assessment. [Eur Heart J 2016, doi: http://dx.doi.org/10.1093/eurheartj/ehw106]
A new clinical decision rule (CDR) offers clinicians clues on when to stop anticoagulation therapy in women who had a first, unprovoked venous thromboembolism (VTE), data from the REVERSE II* study, reported at the ESC Congress 2016, have shown.
Patients with acute coronary syndrome (ACS) caused by plaque erosion could benefit from antithrombotic therapy without stenting, according to results of the EROSION* study presented at the European Society of Cardiology (ESC) Congress 2016 held in Rome, Italy.
Lower levels of low-density lipoprotein cholesterol (LDL-C) combined with a lower systolic blood pressure (SBP) have synergistic effects in reducing the risk of cardiovascular disease (CVD), according to a study presented at the recent European Society of Cardiology (ESC) Congress 2016 held in Rome, Italy.
Recent results of a randomized trial showed that prophylactic placement of an implantable cardioverter defibrillator (ICD) in patients with non-ischaemic heart failure (HF) does not reduce all-cause mortality whether or not the patients are candidates for cardiac resynchronization therapy (CRT).
Lipoprotein apheresis, normally used for lipid control in heterozygous familial hypercholesterolaemia, has shown benefit in patients with refractory angina pectoris and raised lipoprotein(a) [Lp(a)] levels in a small phase III study presented at the European Society of Cardiology (ESC) Congress 2016 held recently in Rome, Italy. [Atheroscler Suppl 2015;18:103-108]
Patients with heterozygous familial hypercholesterolaemia (HeFH) who rely on apheresis treatments for lipid control can significantly decrease or even eliminate this expensive and time-consuming procedure with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab, according to a phase III trial reported at the European Society of Cardiology (ESC) Congress 2016 held recently in Rome, Italy. [Eur Heart J 2016, doi: 10.1093/eurheartj/ehw388]
N-acetylcysteine (NAC), when added to glyceryl trinitrate (GTN), reduces myocardial infarct size by approximately a third in patients with ST-segment elevation MI (STEMI) undergoing percutaneous coronary intervention (PCI), an Australian study has shown. [Pasupathy S, et al, ESC 2016, abstract 2227]